US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,400.59

-3.4864-0.25%

Number of Gainers:3

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,419.10

Open:1,404.67

Low:1,398.60

Close:1,403.95

Volume:6.52M

Turnover:40.35M

Market Cap:22.13B

Float Cap:21.99B

Loading ...

MannKind, United Therapeutics to Develop Second Inhaled Therapy

MT Newswires Live

MannKind Amends License Agreement with United Therapeutics

MannKind Corporation Secures $5 Million Deal with United Therapeutics for Additional Product Development

BRIEF-MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Femasys Inc. Announces Underwritten Public Offering of 10.43M Shares and Pre-Funded Warrants for 11.75M Shares, Raising $8M

Biotech Company Femasys Inc Plunges 35.7% Following Announcement of $8 Million Public Offering

Femasys Inc. Announces $8 Million Public Offering to Fund Expansion and Product Development

Press Release: Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Chief Business and Strategy Officer

MT Newswires Live

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Benzinga_recent_news

H.C. Wainwrights positive on MannKind deal for scPharmaceuticals

scPharmaceuticals downgraded to Hold from Buy at Maxim

MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation

MannKind Shares Down 5.5%

THOMSON REUTERS

scPharmaceuticals Shares Gain 13% After MannKind Buyout Deal

THOMSON REUTERS

BUZZ-scPharmaceuticals rises after MannKind's buyout deal

MannKind Shares Down 1.9%

THOMSON REUTERS

scPharmaceuticals Shares Gain 13% Premarket as MannKind to Acquire Co

THOMSON REUTERS

scPharmaceuticals Announces Merger with MannKind Corporation

MannKind to acquire scPharmaceuticals for up to $6.35 per share in cash

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1400.4594,"timestamp":1756307041184,"preClose":1403.9458,"halted":0,"volume":6517358,"delay":0,"changeRate":-0.002483,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-3.48645,"latestTime":"08-27 11:04:01 EDT","open":1404.6719,"high":1419.0967,"low":1398.5952,"amount":40345236.606145,"amplitude":0.014603,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1756324800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.238483,"peRate":-82.243175,"turnoverRate":0.004342,"increases":3,"decrements":3,"flats":0,"marketCap":22134990661,"floatMarketCap":21987541481},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1419.0967,"amplitude":0.014603,"preClose":1403.9458,"low":1398.5952,"pbRate":"3.238483","latestPrice":1400.5856,"volume":6516014,"delay":0,"open":1404.6719,"prevYearClose":1682.2216,"prevWeekClose":1430.1089,"prevMonthClose":1176.7134,"prevQuarterClose":1256.7808,"fiveDayClose":1363.4373,"twentyDayClose":1276.4644,"sixtyDayClose":1304.5483,"secType":"PLATE","market":"US","turnoverRate":0.004341,"peRate":-82.243175,"marketCap":22136985029,"floatMarketCap":21989497961,"timestamp":1756307036880,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562374917","title":"MannKind, United Therapeutics to Develop Second Inhaled Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2562374917","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562374917?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:39","pubTimestamp":1756298396,"startTime":"0","endTime":"0","summary":"MannKind  said Wednesday that United Therapeutics  has exercised its option to develop a second dry powder inhalation therapy under their 2018 license and collaboration agreement.MannKind said it will receive $5 million upfront, and would be eligible to receive up to $35 million in development milestones and 10% royalties on net sales of any resulting product under the expanded agreement.MannKind said it will immediately start formulating a second investigational molecule via its Technosphere platform. United Therapeutics will conduct preclinical and clinical development, it added.Their collaboration led to the US Food and Drug Administration approval of Tyvaso DPI for pulmonary hypertension in May 2022, MannKind said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MNKD","BK4584","BK4532","LU1699723380.USD","UTHR","LU1571399168.USD"],"gpt_icon":0},{"id":"2562749310","title":"MannKind Amends License Agreement with United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2562749310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562749310?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:28","pubTimestamp":1756297725,"startTime":"0","endTime":"0","summary":"MannKind ( ($MNKD) ) just unveiled an announcement. On August 24, 2025, MannKind Corporation amended its global license agreement with United Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mannkind-amends-license-agreement-with-united-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mannkind-amends-license-agreement-with-united-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4584","MNKD","BK4139","UTHR","LU1571399168.USD","LU1699723380.USD"],"gpt_icon":0},{"id":"2562746395","title":"MannKind Corporation Secures $5 Million Deal with United Therapeutics for Additional Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746395","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746395?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:09","pubTimestamp":1756296554,"startTime":"0","endTime":"0","summary":"MannKind Corporation has announced a significant amendment to its existing global license and collaboration agreement with United Therapeutics Corporation. According to the amendment, MannKind will receive an upfront payment of $5 million and is eligible for up to $35 million in milestone payments related to the development of an additional product. This product will be formulated using MannKind's proprietary Technosphere platform. Additionally, MannKind stands to earn 10% royalties on net sales if the product is approved. Under the agreement, MannKind will manufacture clinical trial materials, while United Therapeutics will oversee preclinical and clinical development activities. This amendment marks an expansion of the original agreement, initially established in September 2018.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL2FdTWG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MNKD","LU1699723380.USD","BK4139","UTHR","LU1571399168.USD","BK4584"],"gpt_icon":0},{"id":"2562746851","title":"BRIEF-MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746851","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746851?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:06","pubTimestamp":1756296395,"startTime":"0","endTime":"0","summary":"BRIEF-MannKind Announces Expansion of United TherapeuticsCollaboration for Second Inhaled TherapyAug 27 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANNOUNCES EXPANSION OF UNITED THERAPEUTICS COLLABORATI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUA8WNBH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2562871288","title":"Femasys Inc. Announces Underwritten Public Offering of 10.43M Shares and Pre-Funded Warrants for 11.75M Shares, Raising $8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2562871288","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562871288?lang=en_us&edition=fundamental","pubTime":"2025-08-27 18:05","pubTimestamp":1756289106,"startTime":"0","endTime":"0","summary":"Femasys Inc. has entered into an underwriting agreement with JonesTrading Institutional Services LLC and Laidlaw & Company  Ltd. for an underwritten public offering of 10,434,586 shares of its common stock and pre-funded warrants to purchase 11,750,000 shares of common stock, accompanied by common warrants to purchase 22,184,586 shares. The combined public offering price for each share of common stock with the accompanying warrant is $0.36. The gross proceeds from the offering are expected to be $8.0 million. Additionally, Femasys will issue warrants to the underwriters to purchase 443,692 shares of common stock at an exercise price of $0.45, exercisable starting six months post-closing and expiring on August 27, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL63kDBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","FEMY","BK4584"],"gpt_icon":0},{"id":"1175252042","title":"Biotech Company Femasys Inc Plunges 35.7% Following Announcement of $8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1175252042","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175252042?lang=en_us&edition=fundamental","pubTime":"2025-08-26 23:10","pubTimestamp":1756221055,"startTime":"0","endTime":"0","summary":"During Tuesday morning trading, shares of biotechnology company Femasys Inc (FEMY) tumbled 35.7% after the company announced a public offering to raise $8 million in capital. The proceeds from the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY","BK4082","BK4584","BK4539"],"gpt_icon":0},{"id":"2562205273","title":"Femasys Inc. Announces $8 Million Public Offering to Fund Expansion and Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2562205273","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562205273?lang=en_us&edition=fundamental","pubTime":"2025-08-26 11:44","pubTimestamp":1756179864,"startTime":"0","endTime":"0","summary":"Femasys Inc. has announced the pricing of an $8.0 million underwritten public offering, with the company planning to use the funds for the expansion of commercial efforts, product development, and other corporate purposes. The offering consists of 10,434,586 shares of common stock and pre-funded warrants for up to 11,750,000 shares, accompanied by common warrants for an aggregate of 22,184,586 shares. The shares and accompanying warrants are priced at $0.36 each, with certain company officers offered at a price of $0.5151. The accompanying common warrants, exercisable immediately, will expire five years from issuance. The offering is expected to close around August 27, 2025, pending customary conditions, with Jones and Laidlaw & Company  Ltd. serving as joint book-running managers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL6DCZng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","FEMY","BK4588","IE00BKPKM429.USD","BK4585","BK4082","NDAQ","BK4584","BK4539","BK4112"],"gpt_icon":0},{"id":"2562205783","title":"Press Release: Femasys Announces Pricing of $8.0 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2562205783","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562205783?lang=en_us&edition=fundamental","pubTime":"2025-08-26 11:44","pubTimestamp":1756179840,"startTime":"0","endTime":"0","summary":"ATLANTA, Aug. 25, 2025  -- Femasys Inc.  , a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, or in lieu thereof, pre-funded warrants to purchase up to 11,750,000 shares of its common stock, together with accompanying common warrants to purchase up to an aggregate of 22,184,586 shares of its common stock. The combined public offering price for each share of common stock and accompanying common warrant is $0.36, except for 87,363 shares and accompanying warrants sold to certain officers of the Company at a price of $0.5151 per share and accompanying warrant. The combined offering price of each pre-funded warrant and accompanying common warrant is $0.3599. Each accompanying common warrant will have an exercise price of $0.36, except for the warra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","UK","BK4233","BK4584","R","BK4539","BK4205","BK4232","FEMY","BK4528","BK4022"],"gpt_icon":0},{"id":"2562206192","title":"Acadia Pharmaceuticals Appoints Konstantina Katcheves as Chief Business and Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2562206192","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562206192?lang=en_us&edition=fundamental","pubTime":"2025-08-26 04:31","pubTimestamp":1756153886,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) appointed Konstantina Katcheves as senior vice president, chief business and strategy officer.Katcheves most recently served as senior vice president, global business development, at Teva Pharmaceuticals Industries (TEVA), Acadia said Monday in a statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","BK4557","LU2065170008.USD","LU2065171311.SGD","BK4231","BK4007","BK4559","BK4588","LU2065171402.SGD","LU2065169927.USD","BK4139","AKR","BK4600","BK4584","BK4596","BK4566","BK4595","BK4585","BK4516","BK4080","STRK","TEVA","ACAD"],"gpt_icon":0},{"id":"2562221915","title":"MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2562221915","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562221915?lang=en_us&edition=fundamental","pubTime":"2025-08-26 01:57","pubTimestamp":1756144620,"startTime":"0","endTime":"0","summary":"MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/25/Business-People--Double-Exposure-And-Han.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/25/Business-People--Double-Exposure-And-Han.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/m-a/25/08/47316036/mannkind-backed-by-blackstone-expands-cardiorenal-focus-with-360-million-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2562226525","title":"H.C. Wainwrights positive on MannKind deal for scPharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2562226525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562226525?lang=en_us&edition=fundamental","pubTime":"2025-08-26 00:10","pubTimestamp":1756138225,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the scPharmaceuticals (SCPH) acquisition positive...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwrights-positive-on-mannkind-deal-for-scpharmaceuticals-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwrights-positive-on-mannkind-deal-for-scpharmaceuticals-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNKD","SCPH","BK4139","BK4007","BK4584"],"gpt_icon":0},{"id":"2562022659","title":"scPharmaceuticals downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2562022659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562022659?lang=en_us&edition=fundamental","pubTime":"2025-08-26 00:05","pubTimestamp":1756137956,"startTime":"0","endTime":"0","summary":"Maxim downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired by MannKind (MNKD) for $5.35 per share in cash a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scpharmaceuticals-downgraded-to-hold-from-buy-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scpharmaceuticals-downgraded-to-hold-from-buy-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SCPH","BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2562226300","title":"MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2562226300","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562226300?lang=en_us&edition=fundamental","pubTime":"2025-08-26 00:05","pubTimestamp":1756137911,"startTime":"0","endTime":"0","summary":"Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on MannKind. The associated price target remains the same with $9.00. Br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mannkinds-strategic-acquisition-of-scpharmaceuticals-a-catalyst-for-future-growth-and-value-creation-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mannkinds-strategic-acquisition-of-scpharmaceuticals-a-catalyst-for-future-growth-and-value-creation-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","MNKD","BK4139"],"gpt_icon":0},{"id":"2562247538","title":"MannKind Shares Down 5.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562247538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562247538?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:36","pubTimestamp":1756128967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0MB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCPH","BK4139","BK4584","MNKD","BK4007"],"gpt_icon":0},{"id":"2562247305","title":"scPharmaceuticals Shares Gain 13% After MannKind Buyout Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2562247305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562247305?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:36","pubTimestamp":1756128967,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCPH","BK4139","BK4007","MNKD","BK4584"],"gpt_icon":0},{"id":"2562241826","title":"BUZZ-scPharmaceuticals rises after MannKind's buyout deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2562241826","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562241826?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:17","pubTimestamp":1756124258,"startTime":"0","endTime":"0","summary":"BUZZ-scPharmaceuticals rises after MannKind's buyout deal ** Shares of drugmaker scPharmaceuticals SCPH.O rise 13.2% to $5.48 premarket ** Biotech firm MannKind Corp's MNKD.O to buy scPharmaceuticals in a deal valued up to $360 million, companies say** MNKD's shares fall 2% to $4.03 premarket** Under the deal, MNKD will pay $5.35 per share upfront in cash, plus offer a non-tradable CVR worth up to $1 per share if certain regulatory and sales milestones are met** The deal will allow MannKind to expand its portfolio beyond orphan lung diseases** SCPH brings Furoscix, an FDA-approved on-body infuser to treat adults with chronic heart failure and kidney disease with over $10 billion market opportunity in U.S., according to the companies** The transaction is expected to close in Q4** Up to last close, MNKD down 36.1%, while SCPH up 37% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nL4N3UH0R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","SCPH","MNKD","BK4139","BK4007"],"gpt_icon":0},{"id":"2562249200","title":"MannKind Shares Down 1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562249200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562249200?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:10","pubTimestamp":1756123814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nL4N3UH0R3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","SCPH","BK4584","BK4139","BK4007"],"gpt_icon":0},{"id":"2562788249","title":"scPharmaceuticals Shares Gain 13% Premarket as MannKind to Acquire Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2562788249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562788249?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:10","pubTimestamp":1756123813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nL4N3UH0R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4139","SCPH","BK4007","MNKD"],"gpt_icon":0},{"id":"2562249591","title":"scPharmaceuticals Announces Merger with MannKind Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2562249591","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562249591?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:59","pubTimestamp":1756123165,"startTime":"0","endTime":"0","summary":"The latest announcement is out from scPharmaceuticals ( ($SCPH) ). On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannK...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scpharmaceuticals-announces-merger-with-mannkind-corporation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scpharmaceuticals-announces-merger-with-mannkind-corporation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2562124692","title":"MannKind to acquire scPharmaceuticals for up to $6.35 per share in cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2562124692","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562124692?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:35","pubTimestamp":1756121740,"startTime":"0","endTime":"0","summary":"07:32 EDT MannKind (MNKD) to acquire scPharmaceuticals (SCPH) for up to $6.35 per share in cash Published first on TheFly – the ultimate source for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mannkind-to-acquire-scpharmaceuticals-for-up-to-6-35-per-share-in-cash-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mannkind-to-acquire-scpharmaceuticals-for-up-to-6-35-per-share-in-cash-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCPH","BK4139","BK4007","MNKD","BK4584"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}